Curriculum
Curriculum
BMT fellowship program is a one-year fellowship structured according to the needs and interests of the fellow as it pertains to their future goals and job opportunities. We use a competency form that aligns with the requirements of the Foundation for the Accreditation of Cellular Therapy as a tool to measure achievements and progress of the fellow through the year.
- Four months outpatient (equally split between CNH and NIH). Continuity clinic: one day a week, every week (except when on inpatient service or vacation or conference)
- Four months inpatient (equally split between CNH and NIH)
- Four months electives (Apheresis, Cell Therapy Lab, HLA lab) and research
- Weekend calls: every other weekend
- Educational conferences: one to two (abstract poster and/or oral presentation is recommended)
- Vacation: four weeks (including weekends)
Research
Fellows will be exposed to cutting-edge clinical and translational research, which includes multiple chimeric antigen receptor products, gene therapy, cytotoxic T cell therapies and multi-institutional transplant therapy trials. It is expected that each fellow will have a research goal that will be developed during their time in the BMTCT Fellowship. Fellows are provided four months of protected time set aside for completion of research projects.
Trainee evaluation and mentorship
Trainees will meet with BMTCT Fellowship Program Directors on a monthly basis to evaluate progress. In addition, fellows are encouraged to identify a clinical and research mentor for more personalized training experience tailored to their specific interests and future job requirements.
Clinical Training
![]()
Fellows will split their time equally between the National Institutes of Health and Children's National. Both hospitals are large tertiary referral centers accepting patients regionally, nationally and internationally. The patients we serve are medically complex and quite diverse. Fellows will be involved in both inpatient and outpatient management of a myriad of diseases, including:
- Malignant diseases
- Hemoglobinopathies
- Inherited errors of immunity (IEI)
- Bone marrow failure syndromes
- Cellular therapy (including CAR-T, viral and tumor specific therapies, mesenchymal stromal cells, among others)
- Gene therapies for hemoglobinopathies
Rotations
![]()
In addition to direct patient care in both institutions, fellows will be strongly encouraged to participate in rotations with ancillary divisions. Rotations will be tailored to the fellow’s future plans, including:
- Apheresis
- Blood bank
- Cellular therapy laboratory
- Donor search
- Immunocompromised infectious disease service
- Leukemia/lymphoma tumor boards
- Primary immunodeficiency clinic
- Hemoglobinopathies clinic
